Cargando…

Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson’s Disease

We investigated in vivo brain nicotinic acetylcholine receptor (nAChR) distribution in cognitively intact subjects with Parkinson’s disease (PD) at an early stage of the disease. Fourteen patients and 13 healthy subjects were imaged with single photon emission computed tomography and the radiotracer...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaias, Ioannis Ugo, Spiegel, Jörg, Brumberg, Joachim, Cosgrove, Kelly P., Marotta, Giorgio, Oishi, Naoya, Higuchi, Takahiro, Küsters, Sebastian, Schiller, Markus, Dillmann, Ulrich, van Dyck, Christopher H., Buck, Andreas, Herrmann, Ken, Schloegl, Susanne, Volkmann, Jens, Lassmann, Michael, Fassbender, Klaus, Lorenz, Reinhard, Samnick, Samuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132266/
https://www.ncbi.nlm.nih.gov/pubmed/25177294
http://dx.doi.org/10.3389/fnagi.2014.00213
_version_ 1782330592900153344
author Isaias, Ioannis Ugo
Spiegel, Jörg
Brumberg, Joachim
Cosgrove, Kelly P.
Marotta, Giorgio
Oishi, Naoya
Higuchi, Takahiro
Küsters, Sebastian
Schiller, Markus
Dillmann, Ulrich
van Dyck, Christopher H.
Buck, Andreas
Herrmann, Ken
Schloegl, Susanne
Volkmann, Jens
Lassmann, Michael
Fassbender, Klaus
Lorenz, Reinhard
Samnick, Samuel
author_facet Isaias, Ioannis Ugo
Spiegel, Jörg
Brumberg, Joachim
Cosgrove, Kelly P.
Marotta, Giorgio
Oishi, Naoya
Higuchi, Takahiro
Küsters, Sebastian
Schiller, Markus
Dillmann, Ulrich
van Dyck, Christopher H.
Buck, Andreas
Herrmann, Ken
Schloegl, Susanne
Volkmann, Jens
Lassmann, Michael
Fassbender, Klaus
Lorenz, Reinhard
Samnick, Samuel
author_sort Isaias, Ioannis Ugo
collection PubMed
description We investigated in vivo brain nicotinic acetylcholine receptor (nAChR) distribution in cognitively intact subjects with Parkinson’s disease (PD) at an early stage of the disease. Fourteen patients and 13 healthy subjects were imaged with single photon emission computed tomography and the radiotracer 5-[(123)I]iodo-3-[2(S)-2-azetidinylmethoxy]pyridine ([(123)I]5IA). Patients were selected according to several criteria, including short duration of motor signs (<7 years) and normal scores at an extensive neuropsychological evaluation. In PD patients, nAChR density was significantly higher in the putamen, the insular cortex and the supplementary motor area and lower in the caudate nucleus, the orbitofrontal cortex, and the middle temporal gyrus. Disease duration positively correlated with nAChR density in the putamen ipsilateral (ρ = 0.56, p < 0.05) but not contralateral (ρ = 0.49, p = 0.07) to the clinically most affected hemibody. We observed, for the first time in vivo, higher nAChR density in brain regions of the motor and limbic basal ganglia circuits of subjects with PD. Our findings support the notion of an up-regulated cholinergic activity at the striatal and possibly cortical level in cognitively intact PD patients at an early stage of disease.
format Online
Article
Text
id pubmed-4132266
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-41322662014-08-29 Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson’s Disease Isaias, Ioannis Ugo Spiegel, Jörg Brumberg, Joachim Cosgrove, Kelly P. Marotta, Giorgio Oishi, Naoya Higuchi, Takahiro Küsters, Sebastian Schiller, Markus Dillmann, Ulrich van Dyck, Christopher H. Buck, Andreas Herrmann, Ken Schloegl, Susanne Volkmann, Jens Lassmann, Michael Fassbender, Klaus Lorenz, Reinhard Samnick, Samuel Front Aging Neurosci Neuroscience We investigated in vivo brain nicotinic acetylcholine receptor (nAChR) distribution in cognitively intact subjects with Parkinson’s disease (PD) at an early stage of the disease. Fourteen patients and 13 healthy subjects were imaged with single photon emission computed tomography and the radiotracer 5-[(123)I]iodo-3-[2(S)-2-azetidinylmethoxy]pyridine ([(123)I]5IA). Patients were selected according to several criteria, including short duration of motor signs (<7 years) and normal scores at an extensive neuropsychological evaluation. In PD patients, nAChR density was significantly higher in the putamen, the insular cortex and the supplementary motor area and lower in the caudate nucleus, the orbitofrontal cortex, and the middle temporal gyrus. Disease duration positively correlated with nAChR density in the putamen ipsilateral (ρ = 0.56, p < 0.05) but not contralateral (ρ = 0.49, p = 0.07) to the clinically most affected hemibody. We observed, for the first time in vivo, higher nAChR density in brain regions of the motor and limbic basal ganglia circuits of subjects with PD. Our findings support the notion of an up-regulated cholinergic activity at the striatal and possibly cortical level in cognitively intact PD patients at an early stage of disease. Frontiers Media S.A. 2014-08-14 /pmc/articles/PMC4132266/ /pubmed/25177294 http://dx.doi.org/10.3389/fnagi.2014.00213 Text en Copyright © 2014 Isaias, Spiegel, Brumberg, Cosgrove, Marotta, Oishi, Higuchi, Küsters, Schiller, Dillmann, van Dyck, Buck, Herrmann, Schloegl, Volkmann, Lassmann, Fassbender, Lorenz and Samnick. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Isaias, Ioannis Ugo
Spiegel, Jörg
Brumberg, Joachim
Cosgrove, Kelly P.
Marotta, Giorgio
Oishi, Naoya
Higuchi, Takahiro
Küsters, Sebastian
Schiller, Markus
Dillmann, Ulrich
van Dyck, Christopher H.
Buck, Andreas
Herrmann, Ken
Schloegl, Susanne
Volkmann, Jens
Lassmann, Michael
Fassbender, Klaus
Lorenz, Reinhard
Samnick, Samuel
Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson’s Disease
title Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson’s Disease
title_full Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson’s Disease
title_fullStr Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson’s Disease
title_full_unstemmed Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson’s Disease
title_short Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson’s Disease
title_sort nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of parkinson’s disease
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132266/
https://www.ncbi.nlm.nih.gov/pubmed/25177294
http://dx.doi.org/10.3389/fnagi.2014.00213
work_keys_str_mv AT isaiasioannisugo nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT spiegeljorg nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT brumbergjoachim nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT cosgrovekellyp nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT marottagiorgio nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT oishinaoya nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT higuchitakahiro nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT kusterssebastian nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT schillermarkus nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT dillmannulrich nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT vandyckchristopherh nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT buckandreas nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT herrmannken nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT schloeglsusanne nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT volkmannjens nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT lassmannmichael nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT fassbenderklaus nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT lorenzreinhard nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease
AT samnicksamuel nicotinicacetylcholinereceptordensityincognitivelyintactsubjectsatanearlystageofparkinsonsdisease